Phase 3 N=891 Diagnosis of Acute Appendicitis: Low-dose Computed Tomography (CT) Versus Standard-dose CT
Appendicitis
Primary: Negative Appendectomy — 6; 6; 166; 180 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=105 Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma
Retinoblastoma · Retinal Neoplasm
Primary: Stratum B Response to Window Therapy — 24; 2; 1 Participants
Phase 3 N=121 Effects on Hemostasis, Lipids, Carbohydrate Metabolism, Adrenal & Thyroid Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG-EE (292004)(COMPLETED)(P05764)
Contraception
Primary: Serum Concentration of Prothrombin Fragments 1 + 2 — 0.18; 0.19; 0.31; 0.42 nmol/L — p=0.0849
Phase 3 N=48 Effects on Ovarian Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292003)(COMPLETED)(P05723)
Contraception
Primary: Effect on Ovarian Function as Determined by the Number of Participants With an Occurrence of Ovulation — 0; 0; 0; 0 Participants
Phase 3 N=179 Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan
Type 2 Diabetes Mellitus
Primary: Number of Participants With Adverse Events. — 6; 7; 0; 1 participants
Phase 3 N=123 Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis
Cystic Fibrosis
Primary: Time to Recurrence of Pseudomonas (P.) Aeruginosa (Any Genotype) in Sputum or Deep Throat Cough Swab — 26.12; 25.82 Months
Phase 3 N=110 Effects on Bone Mineral Density (BMD) of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG/EE (292005)(P05765)(COMPLETED)
Contraception
Primary: Mean Change From Baseline in Z-scores of the Lumbar Spine (L2-L4) and Femoral Neck — 0.019; 0.121; -0.007; 0.044 score on a scale — p=0.19
Phase 3 N=2,126 Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared to a COC Containing DRSP/EE (292001)(COMPLETED)(P05724)
Contraception
Primary: Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index) — 0.467; 1.017; 0.571; 1.261 Pregnancies per 100 woman years
Phase 3 N=2,220 Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722)
Contraception
Primary: Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index) — 1.754; 3.005; 1.963; 3.092 Pregnancies per 100 woman years
Phase 3 N=329 Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes
Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26. — -0.02; -0.56; -0.59 percentage of Glycosylated Hemoglobin — p=<0.001
Phase 3 N=178 Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents
Migraine Disorders
Primary: Percentage of Participants Who Reported Pain Relief at 120 Minutes Post-Treatment — 38.6; 31.1 percentage of participants — p=0.345
Phase 3 N=121 A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)
Fungal Infection
Primary: Number of Participants With a Significant Drug-related Adverse Experience — 3; 6 Participants
Phase 3 N=410 Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
Skin Infections, Bacterial
Primary: Number of Participants Achieving Clinical Response at Follow-up Who Had Methicillin-resistant Staphlococcus Aureus (MRSA) as a Baseline Pathogen — 41; 32 participants
Phase 3 N=500 Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.
Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26. — 0.01; -0.38; -0.52 mg/dL — p=<0.001
Phase 3 N=511 Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).
Parkinson Disease
Primary: Percentage of Patients With Adverse Events, Adverse Drug Reactions, Serious Adverse Events — 84.5; 76.2; 45.7; 23.1 Percentage of participants